Flubromazolam
Flubromazolam is a triazolobenzodiazepine, which are benzodiazepine derivatives. Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg. Life-threatening adverse reactions have been observed at doses of only 3 mg of flubromazolam.
Legal status
Sweden
Flubromazolam has been classified as an illegal substance in Sweden after seizures by customs and police, as well as indications from the EMCDDA of wider use as a recreational drug.
Flubromazolam is illegal in Switzerland as of December 2015.
United Kingdom
In the UK, flubromazolam has been classified as a Drugs controlled by the UK [Misuse of Drugs Act|Class C drug] by the May 2017 amendment to Misuse of [Drugs Act 1971|The Misuse of Drugs Act 1971] along with several other designer benzodiazepine drugs.
Australia
In Australia, flubromazolam is Standard [for the Uniform Scheduling of Medicines and Poisons#Schedule 9: Prohibited Substance|Schedule 9] under federal law.
United States
Flubromazolam is controlled in Virginia and Wisconsin. On 23 December 2022, the DEA announced it had begun consideration on the matter of placing Flubromazolam under temporary Schedule I status. Later on 25 July 2023, the DEA published a pre-print notice that Flubromazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025. On July 25, 2025, and effective the following day, the DEA extended the temporary scheduling until July 26, 2026.